Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07498829

Population Based Germline Testing for Early Detection and Prevention of Cancer

Population Based Germline Testing for Early Detection and Prevention of Cancer — Recruiting • Non-phase study • Oncology • NCT07498829.

📅 27 Mar 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07498829
Sponsor
Queen Mary University of London
Start
2025-12-18
ClinicaliQ Trial Snapshot
  • Population Based Germline Testing for Early Detection and Prevention of Cancer — Recruiting • Non-phase study • Oncology • NCT07498829.
  • PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer. This is regardless of whether they or their families have had cancer. Breast,….
  • Sponsor: Queen Mary University of London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer. This is regardless of whether they or their families have had cancer. Breast, ovary, bowel, and womb cancers make up half of all cancers in women. Around 15-20% (15 to 20 in 100 cases) of ovary and 3-4% (3 to 4 in 100 cases) of breast, womb, and bowel cancers are linked to cancer genes and may be prevented. People with…

Eligibility Snapshot
  • : * Women, trans men, and non-binary people with female reproductive organs * ≥18 years at consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Clinical Brief
Breast cancer checks missing most women under 50 who are at risk, says study
Oncology · BBC Health · 04 Aug 2026
Current NHS breast screening programmes fail to identify approximately 95% of women under 50 at higher genetic or familial risk of breast…
View brief →
Guideline
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Oncology · 24 Jun 2026
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα…
View guideline →
Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Clinical Brief
Lucy Davis urges women to check their breasts for cancer – here’s how
Oncology · BBC Health · 12 Aug 2026
Breast cancer can present as subtle findings—a hard spot rather than a discrete lump—emphasising the importance of thorough self-examination and patient awareness…
View brief →
Guideline
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Oncology · 18 Jun 2026
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer…
View guideline →